Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7211671B2 · kind B2 · utility
14Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2004 |
| Grant date | May 1, 2007 |
| Priority date | — |
| Expiry date | Jun 3, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I):or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.